treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone does the addition of systemic bevacizumab improve results objectives this study investigated the efficacy and safety of adding systemic iv bevacizumab bev to hepatic arterial infusion hai with floxuridine fudrdexamethasone dex in unresectable primary liver cancermethods patients with unresectable intrahepatic cholangiocarcinoma icc or hepatocellular carcinoma hcc were treated with hai fudrdex plus iv bev results were compared to a recent study of hai without bev in a similar patient populationresults twentytwo patients 18 icc 4 hcc were treated with hai fudrdex plus bev 7 318 had partial response and 15 682 had stable disease median survival was 311 months ci 14143359 progressionfree survival pfs 845 months ci 5531105 and hepatic pfs 113 months ci 7931569 in the previous trial with hai alone no bev the response was 50 median survival pfs and hepatic pfs were 295 73 and 101 months in the present trial bilirubin elevation 2 mgdl was seen in 24 of patients and biliary stents were placed in 136 versus 58 and 0 respectively in the hai trial without bev due to increased biliary toxicity the trial was prematurely terminatedconclusion adding bev to hai fudrdex appeared to increase biliary toxicity without clear improvement in outcome median pfs 845 vs 73 months and median survival 311 vs 295 months for hai bev vs hai alone groups respectively